Core Viewpoint - Revvity Inc is experiencing strong financial performance and growth potential, as indicated by a positive price target from Evercore ISI and impressive earnings results for 2025 [1][2]. Financial Performance - Revvity Inc reported adjusted earnings per share (EPS) of $5.06 for 2025, surpassing its guidance and showcasing effective navigation of challenges [2]. - The company achieved a 3% organic growth for the year, aligning with its original guidance range [2]. Segment Performance - In the fourth quarter, Revvity's diagnostics segment saw a notable 7% organic growth, driven by strong performance in immunodiagnostics, indicating resilience and agility [3]. Strategic Actions - The company repurchased over $800 million worth of shares in 2025, reducing its share count by 8.5 million shares, reflecting commitment to growth initiatives despite headwinds [4]. Stock Performance - Currently, RVTY's stock price is $107.09, with a decrease of 1.57% today, and a market capitalization of approximately $12.43 billion [5]. - Over the past year, RVTY has seen a high of $124.82 and a low of $81.36, with today's trading volume at 2,888,170 shares [5].

Revvity, Inc. ( RVTY ) is a mid-cap U.S.-based company that used to be part of PerkinElmer, but a few years ago it split off to focus on products and services used inI focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Revvity Inc. (NYSE:RVTY) on Monday reported better-than-expected earnings for the fourth quarter.The company posted fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55. The life sciences and diagnostics company reported sales of $772.06 million, up 6% (+4% organic growth), surpassing the consensus of $761.29 million."We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations," said Prahlad Singh, president ...

Group 1 - Revvity, Inc. reported fourth-quarter results that exceeded analyst expectations for both earnings and revenue, with adjusted earnings per share at $1.70 compared to the consensus estimate of $1.55 and revenue totaling $772.06 million, surpassing expectations of $758.53 million [1] - Quarterly revenue increased by 6% from $729 million a year earlier, with organic growth of 4%. GAAP earnings per share rose to $0.87 from $0.78 in the prior-year period [2] - The Diagnostics segment led performance with a 10% increase in revenue to $390 million, including 7% organic growth, while Life Sciences revenue increased by 2% to $382 million, though organic revenue for this segment was flat year over year [2] Group 2 - For the full year 2025, Revvity reported adjusted earnings per share of $5.06, up from $4.90 in 2024, while total revenue rose to $2.86 billion from $2.76 billion [3] - Looking ahead, the company initiated fiscal 2026 guidance, projecting revenue of $2.96 billion to $2.99 billion, above the $2.94 billion consensus estimate, and adjusted earnings per share were forecast at $5.35 to $5.45, exceeding analyst expectations of $5.32 [3]

Core Insights - Revvity, Inc. reported strong financial performance in the fourth quarter, with an EPS of $1.70, exceeding the estimated $1.63 and improving from $1.42 in the same quarter last year [1][6] - The company generated approximately $772.1 million in revenue, surpassing the forecasted $763.1 million and increasing from $729.37 million reported in the previous year [3][6] - RVTY has consistently outperformed consensus EPS estimates over the past four quarters, indicating robust financial health and operational efficiency [2] Financial Metrics - The company's price-to-earnings (P/E) ratio is approximately 50.83, reflecting strong investor confidence in its earnings potential [4][6] - RVTY's price-to-sales ratio stands at about 4.25, and the enterprise value to sales ratio is around 5.11, suggesting solid valuation relative to sales [4] - The enterprise value to operating cash flow ratio is approximately 25, and the earnings yield is about 1.97%, providing insight into the return on investment for shareholders [5] - RVTY's debt-to-equity ratio is approximately 0.46, indicating a moderate level of debt relative to equity, while the current ratio of about 1.75 suggests good liquidity to cover short-term liabilities [5]

Reproductive Health grew mid-single digits organically in the quarter and for the year. Management said newborn screening grew mid-single digits in the quarter and high single digits for the full year and cited contributions from work with Genomics England.Immunodiagnostics grew high single digits organically in the quarter and mid-single digits for the full year, with strength outside China partially offset by double-digit declines in China for the full year due to DRG-related volume pressures.Management s ...

Revvity (RVTY) reported $772.06 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 5.9%. EPS of $1.70 for the same period compares to $1.42 a year ago.The reported revenue represents a surprise of +0.02% over the Zacks Consensus Estimate of $771.9 million. With the consensus EPS estimate being $1.63, the EPS surprise was +4.29%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Revvity Inc. (NYSE:RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.Adjusted operating income was $229 million, as compared to $221 million a year ago.Adjusted operating profit margin was 29.7% compared to 30.3% a year ago.The life sciences and diagnostics company reported sales of $772.06 million, up 6% (+4% organic growth), surpassing the consensus of $761.29 million.“We finished 2025 on a strong note by delivering r ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $772 million, resulting in 4% organic growth, with a full year revenue of $2.86 billion, reflecting 3% organic growth [22][24] - Adjusted EPS for the fourth quarter was $1.70, exceeding the high end of expectations, while the full year adjusted EPS was $5.06, representing 3% growth year-over-year [10][24] - Adjusted operating margins for the fourth quarter were 29.7%, down 60 basis points year-over-year, while full year adjusted operating margins were 27.1%, down 120 basis points year-over-year [23][24] Business Line Data and Key Metrics Changes - The diagnostics segment generated $390 million in revenue for the fourth quarter, up 10% on a reported basis and 7% on an organic basis, with full year organic growth of 4% [28] - The life sciences segment reported revenue of $382 million in the fourth quarter, flat on an organic basis, with full year organic growth also at 2% [26][27] - The immunodiagnostics business grew in the high single digits organically in the fourth quarter, while the reproductive health business grew mid-single digits [28][30] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, while Europe saw double-digit growth [26] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [26] Company Strategy and Development Direction - The company plans to continue its focus on capital deployment, including share repurchases and potential acquisitions, while maintaining a disciplined approach [11][20] - The introduction of the AI models-as-a-service platform, Signals Synthetica, is expected to enhance the company's position in the market [15][16] - The company anticipates organic growth of 2%-3% for 2026, with potential upside if market conditions improve [12][31] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, particularly in pharma and biotech, while acknowledging ongoing uncertainties [11][12] - The company noted improvements in customer sentiment and funding in the biotech sector, contributing to a more favorable outlook [52] - Management emphasized the importance of maintaining a prudent approach in light of recent market trends and uncertainties [12][31] Other Important Information - The company repurchased over $800 million worth of shares in 2025, reducing the share count by 8.5 million shares [10][11] - The acquisition of ACD/Labs is expected to contribute over $20 million in revenue for the year, adding approximately 75 basis points to overall revenue growth [13][31] Q&A Session Summary Question: Can you provide more color on the 2%-3% organic growth guidance? - Management acknowledged positive signs in end markets since September but maintained the conservative guidance to allow for potential upside as the year unfolds [39][40] Question: What is driving the strength in instruments and reagents within life sciences? - Management indicated that continued momentum in the end market and share gains in the preclinical market are contributing factors [45] Question: Can you elaborate on the timing and trajectory of new software products? - Management highlighted that the Signals business is in a significant new product introduction phase, with expectations for growth to accelerate in the coming years [48][49] Question: How is the company approaching M&A opportunities? - Management stated that any potential M&A must provide a strong strategic addition and meet financial return criteria [56] Question: What are the expectations for the diagnostics business going into 2026? - Management expressed a more prudent assumption for newborn screening and immunodiagnostics in China, while still anticipating potential upside [64][70]